A 'super test' for prostate cancer is set to look for more than 100 signs of the disease.
The 'real game -changing' test, welcomed by former Olympic cycling champion Sir Chris Hoy and hoped to be the most accurate tool to date for detecting the disease, will show whether someone has prostate cancer and whether that cancer is slowly growing or aggressive.
It looks for organic markers of prostate cancer, including proteins and genes, which are analyzed by an AI algorithm to produce a result.
Prostate cancer is the most common cancer in England, about one in eight men will get it within their lives, and every year more than 50,000 men are diagnosed in the UK.
There is no current screening for prostate cancer in healthy men because the PSA test used by doctors when men have symptoms or is not accurate enough on request.
The new test, used on blood and urine monsters, is looking for more than 100 biological markers of prostate cancer, which has been established to detect the disease when they are studied individually.
Scientists expect it to be 96 to 99 percent accurate, based on this earlier evidence.
The test was developed by EDX Medical Group, based in Cambridge Science Park, and is hoped to be launched, with regulatory approval, later this year or early 2026.
A 'super test' for prostate cancer is set to look for more than 100 signs of the disease (stock image)
The 'real game -changing' test was welcomed by former Olympic cycling champion Sir Chris Hoy (photo) who announced in October that he had a terminal diagnosis for prostate cancer, after he had been told by doctors in 2023 that he had two to four years to live for two to four years
Professor Sir Chris Evans, the founder and chief scientific officer of EDX Medical, said: “We have been studying this area for 18 months and are extremely excited about what we think is a real game -changing test.”
He added: “The inclusion of all these biomarkers in routine screening can cause a revolution in the management of prostate cancer by making previous detection and more accurate risk prediction possible.”
Sir Chris Hoy, who announced in October that he had a terminal diagnosis for prostate cancer, after he had been told by doctors in 2023 that he had two to four years to live, said: “Professor Sir Chris Evans and his team encouraged me and encouraged me and encouraged me I supported me enormously after my first diagnosis and I know they have some great people and a great dedication to find better ways to diagnose and treat prostate and other cancers.
“I now know that there is a need for better and more accurate screening tests of prostate cancer, and I wholeheartedly welcome this initiative.”
The government looks 'carefully' in introducing routine screening on prostate cancer, such as technology progress, said Health Minister Andrew Gwynne earlier this month.
During the new test, Simon Gieveson, assistant director of research at Prostate Cancer UK,: 'In recent years we have seen various emerging tests in development that demonstrate a big promise when it comes to the early detection of prostate cancer.
'We welcome highly vaults that can lead to more accurate and earlier diagnoses, but many of these tests are still very early in their development and require robust tests in clinical studies before we can know with certainty how useful they can be.
“Early and important, accurate diagnosis, the diagnosis can prevent up to 40 percent of the deaths by prostate cancer – that are thousands of lives per year.”
